The World Health Organization has publicly condemned a vaccine trial in Guinea-Bissau, calling it unethical. The trial, funded by the United States, involves withholding a proven, lifesaving hepatitis B vaccine from some newborns. WHO officials argue that the study violates essential ethical and scientific standards, raising concerns about the safety and integrity of the research.

Details of the Controversial Trial

The vaccine trial was announced after the Centers for Disease Control and Prevention (CDC) awarded $1.6 million to Danish researchers. This funding, awarded under the Trump-era administration, was part of a proposal to test alternative vaccination strategies in Guinea-Bissau. The trial aims to compare different approaches to administering the hepatitis B vaccine to newborns, but critics say it involves withholding a vaccine known to prevent serious disease.

According to publicly available information, the trial would delay or skip the standard hepatitis B vaccination for some infants, leaving them unprotected in a region with high rates of the disease. Many health experts warn that such a design risks exposing vulnerable babies to preventable illnesses and undermines established immunization protocols.

WHO’s Concerns and Ethical Violations

The WHO’s statement emphasized that the trial is “inconsistent with established ethical and scientific principles.” They highlighted that withholding a proven vaccine from newborns could lead to avoidable health risks and possibly increase hepatitis B transmission. The organization also criticized the trial’s scientific validity, arguing that the design lacks sufficient justification and does not adhere to international research standards.

WHO officials pointed out that the trial’s low-quality approach and potential harm outweigh any possible benefits. They stressed that ethical research must prioritize the safety and well-being of participants, especially vulnerable populations like newborns. Conducting studies that could jeopardize their health is considered unacceptable by global health standards.

The controversy has sparked widespread condemnation from health experts worldwide. Critics argue that the trial appears driven by research interests rather than public health needs, and that it undermines trust in vaccination programs, especially in low-income countries where vaccine confidence is critical.

This incident has also reignited debates over the role of US funding in global health research. Opponents say that such trials should only be conducted if they align with international ethical guidelines and prioritize community health. The WHO’s stance serves as a reminder that safeguarding human rights and scientific integrity must come first in any medical research, especially involving vulnerable populations like newborns in Africa.

Inspired by

• https://arstechnica.com/health/2026/02/who-slams-us-funded-newborn-vaccine-trial-as-unethical/

Sources

• who.int
• federalregister.gov
• science.org
• npr.org
• nature.com